LY2452473 + tadalafil

**LY2452473 + tadalafil** is a combination of two small-molecule drugs: LY2452473, an investigational selective androgen receptor modulator (SARM), and tadalafil, a phosphodiesterase type 5 (PDE5) inhibitor best known for its use in erectile dysfunction and benign prostatic hyperplasia. LY2452473 is designed to selectively modulate androgen receptor activity, potentially enhancing anabolic effects while minimizing androgenic side effects. Tadalafil increases cyclic GMP by inhibiting PDE5, resulting in smooth muscle relaxation and improved blood flow. The combination has been investigated for synergistic effects in conditions such as erectile dysfunction, potentially offering both improved sexual function and additional anabolic or metabolic benefits. Both agents are administered orally and have undergone co-administration in early-phase clinical trials, including head-to-head and combination formulation pharmacokinetics studies led by Eli Lilly and Company[1][2][3][4][5].

Other names

LY900010LY-900010LY 900010